著者
中島 理恵 白神 誠
出版者
日本社会薬学会
雑誌
社会薬学 (ISSN:09110585)
巻号頁・発行日
vol.37, no.1, pp.9-18, 2018-06-10 (Released:2018-07-10)
参考文献数
14

When establishing new pharmacy services, they must be in line with the needs of individual community residents. In our research, it was clear that services provided by the newly implemented health support pharmacies and primary care pharmacist system in recent years satisfy the needs of patients as well as the public in general. We collected information via a survey that used a structured questionnaire. In addition to basic information (age/sex), it also covered details of their pharmacy use, their thoughts on pharmacy services, and the actual usability of pharmacy services. Differences in respondent’s opinions and the actual usability of each pharmacy service were compared between age groups and sexes. Female respondents had more favorable opinions about the antismoking, nutrition, and sickness prevention consultation services than male respondents did. The proportion of survey respondents in their 40s and 50s who proactively used pension and welfare consultation services was significantly higher than for other age groups. The younger generation perceived 24-hour pharmacies and the primary care pharmacy system as necessary. There is a large disparity between people’s thoughts and opinions on the actual usability of the services that primary care pharmacies aim to offer, and this differ in people’s ages and sexes. The younger generation tend to expect the pharmacy services. It is important for pharmacies to address the needs of the generation which is skeptical toward the separation of medical and dispensary practice and recognize them the new role of pharmacies.
著者
中島 理恵
出版者
一般社団法人 レギュラトリーサイエンス学会
雑誌
レギュラトリーサイエンス学会誌 (ISSN:21857113)
巻号頁・発行日
vol.7, no.2, pp.81-89, 2017 (Released:2017-05-31)
参考文献数
14

製薬企業が行うプロモーションのなかには虚偽や誤解を招く表現を用いているものも存在する. このような状況は最終的には医薬品を使用する患者の不利益につながるため, 第3者による製薬企業の新薬プロモーション活動の監視制度の確立が求められている. 本研究では, 我が国における製薬企業の医薬品プロモーション活動の監視制度の在り方を検討するため, すでに製薬企業の医薬品プロモーションの監視活動を行っている米国FDA (Food and Drug Administration) の取り組みを例示するとともに, 米国における医薬品広告違反の実態をFDAから発行されたwarning letterとuntitled letterを参考にして分析した. FDAでは, 疾病専門領域ごとの担当審査官を設置し, 膨大で専門的なプロモーション資材を効率良くレビューしている. また, 医局や講演会といったFDAの目が届きにくい現場でのプロモーション違反対策として, 現場の医療従事者に向け, 教育と報告窓口の両方の側面をもつBad Ad Programの制度を提供している. 米国においては, 近年電子媒体での違反が増加しており, 今後はFacebookなどのソーシャルメディアからの情報の監視が重要となる.
著者
藤田 優子 中島 理恵 小野寺 祐加 白神 誠
出版者
一般社団法人日本医薬品情報学会
雑誌
医薬品情報学 (ISSN:13451464)
巻号頁・発行日
vol.16, no.1, pp.23-27, 2014-05-30 (Released:2014-06-09)
参考文献数
3

Introduction: A health assessment sheet was developed to establish a new method for post marketing surveillance (PMS) for nonprescription drugs, the status of which has recently been switched from prescription (Rx) to over-the-counter (OTC) to confirm the efficacy and safety of Rx-to-OTC switched drugs.  The assessment sheet was designed to evaluate adverse reactions that may be possibly induced by the drugs and to elicit spontaneous complaints from consumers.  An investigation using the assessment sheet had been conducted earlier for famotidine tablets.  While the earlier investigation suggested the effectiveness of the assessment method, it also revealed some issues.  After making improvements in the assessment sheet, another investigation was conducted for Loxonin®S.Method: Purchasers of Loxonin®S were asked to tick symptoms that were applicable to them among those listed in the sheet.  They were asked to revisit the pharmacy and complete the sheet for the second time after drug administration.  The possibility of adverse reactions was considered for the symptoms additionally chosen at the second visit and they were then compared with the adverse reactions described in the package insert of Loxonin®S.Results: Total 284 people completed the health assessment sheet at their first and second visits.  Of them, 44 people (15.5%) reported additional symptoms at the second visit.  Commonly reported symptom was “frequent experience of sleepiness,” “persistent headaches” and “fatigability.”Conclusion: The study suggested that the health assessment sheet can be an effective tool for PMS for nonprescription drugs immediately after the Rx-to-OTC switch and contributes to detecting adverse reactions of the drugs.